In a groundbreaking development, scientists in the UK have found a new, more effective way to manage asthma and chronic obstructive pulmonary disease (COPD). This breakthrough, hailed as the first major advancement in 50 years, offers a promising alternative to the long-standing use of steroids, a common treatment that can have significant side effects.
The study, published in The Lancet Respiratory Medicine, presents benralizumab, a monoclonal antibody that targets white blood cells to reduce inflammation in the lungs. While steroids are commonly used to treat flare-ups in both asthma and COPD patients, they do not work for everyone and can have long-term adverse effects, such as high blood pressure and osteoporosis. The new treatment option could transform how these respiratory conditions are managed, especially for patients who do not respond well to steroids.
How the New Treatment Works
Typically, patients with eosinophilic exacerbations—a type of flare-up that accounts for about half of asthma attacks and 30% of COPD attacks—are given a five-day steroid course to alleviate symptoms like wheezing, coughing, and chest tightness. However, this approach is not universally effective, and many patients still struggle with ongoing symptoms or the need for additional treatment.
The trial that led to the discovery of benralizumab’s effectiveness involved dividing participants into three groups: one group received benralizumab, another group received steroids, and the third group received both treatments. The results were promising. After 28 days, patients who received benralizumab showed improved respiratory outcomes. After 90 days, 74% of patients who had taken steroids required additional medical attention, compared to just 45% of those who received the monoclonal antibody injection.
The Potential Impact of Benralizumab
This new treatment could significantly reduce the need for steroids, offering relief from their side effects and improving the overall quality of life for patients. The study’s lead investigator, Dr. Mona Bafadhel from King’s College London, called it a "game-changer" for people suffering from these chronic respiratory conditions.
In Europe alone, nearly 36.6 million people suffer from COPD, and asthma affects approximately 10 million individuals under the age of 45. The conditions not only impact daily life but also significantly reduce life expectancy, particularly for those who have both asthma and COPD. With benralizumab offering an alternative to traditional treatments, the hope is that these patients will see improved outcomes.
Looking Forward: A New Era of Treatment
This breakthrough comes at a crucial time, as the current treatments for asthma and COPD are often seen as outdated. “We need to provide these patients with life-saving options before their time runs out,” said Dr. Sanjay Ramakrishnan, one of the study’s authors. With new approaches like benralizumab, scientists hope to change the landscape of treatment for millions worldwide.
Benralizumab’s promise lies not just in its ability to alleviate symptoms but also in its potential to prevent the need for emergency care, reducing hospital visits and improving long-term health outcomes. This study marks a significant step forward in asthma and COPD care, offering patients a new avenue for symptom management and better quality of life.
The trial was supported by AstraZeneca and the University of Oxford, and the ongoing research aims to refine the treatment’s use further.
As the healthcare industry continues to evolve, treatments like benralizumab offer hope for patients suffering from respiratory conditions, heralding a new era of more personalized, effective, and less invasive care.
Source: Euronews
Commentaires